Journal of psychopharmacology (Oxford, England)
August 25, 2026
Praachi Tiwari, Bryan W Jenkins, Catherine F Moore et al.
Psychedelics have emerged as promising pharmacological agents for treating a range of neuropsychiatric disorders. While preclinical studies have provided valuable insight into the neural mechanisms underlying their effects, systematic characterization of psychedelic effects on inherent spontaneous behaviors in animal models remains limited. In the current study, male and female Sprague-Dawley...
JAMA Network Open
May 1, 2026
C Austin Zamarripa, Spencer Lin, Mckenna Klausner et al.
Simultaneous cannabis and alcohol use (co-use) is a public safety concern. Controlled data on the effects of co-ingestion of oral cannabis products (edibles) with alcohol are lacking, despite an increased prevalence of this behavior. To evaluate the individual and interactive effects of cannabis edibles and alcohol on simulated driving and subjective and objective impairment measures. This...
Psychopharmacology
May 1, 2026
Catherine F Moore, Elise M Weerts
Animal models of cannabinoid self-administration are critical for advancing our understanding of the neurobiology of cannabis use and for developing medications for Cannabis Use Disorder. Use of vapor inhalation models have translational relevance, as the majority of humans who use cannabis do so by inhalation (e.g., smoking, vaporization). Adult male and female Sprague Dawley rats (N = 96,...
Journal of psychopharmacology (Oxford, England)
2026
Jack E Henningfield, Frederick S. Barrett, Suzette M Evans et al.
This review provides an overview of Roland R. Griffiths' history of research, and his mentoring and collaborating approach to science that contributed to his impact in behavioral and neuropsychopharmacology and psychedelic medicines development. The approach was to summarize studies in his major domains of research, including preclinical and clinical abuse liability assessment science, alcohol,...